{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:29:39Z","timestamp":1784575779685,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008252","name":"Universit\u00e0 degli Studi di Udine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40262-020-00933-8","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T21:05:14Z","timestamp":1598562314000},"page":"1251-1260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6"],"prefix":"10.1007","volume":"59","author":[{"given":"Pier Giorgio","family":"Cojutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Londero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Della Siega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Givone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Biasizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"933_CR1","unstructured":"WHO. Coronavirus disease (COVID-19) situation reports. 2020 [cited 30 July 2020]. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 31 July 2020."},{"issue":"10231","key":"933_CR2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","volume":"395","author":"A Remuzzi","year":"2020","unstructured":"Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225\u20138.","journal-title":"Lancet"},{"issue":"5","key":"933_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","volume":"39","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405\u20137.","journal-title":"J Heart Lung Transplant"},{"issue":"10229","key":"933_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet"},{"issue":"7","key":"933_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1\u201311. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"933_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","volume":"41","author":"MP Lythgoe","year":"2020","unstructured":"Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41(6):363\u201382.","journal-title":"Trends Pharmacol Sci"},{"key":"933_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa190","author":"S Baldelli","year":"2020","unstructured":"Baldelli S, Corbellino M, Clementi E, Cattaneo D, Gervasoni C. Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa190(Epub 14 May 2020).","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"933_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/jcph.290","volume":"54","author":"TN Kakuda","year":"2014","unstructured":"Kakuda TN, Opsomer M, Timmers M, Iterbeke K, Van De Casteele T, Hillewaert V, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54(8):949\u201357.","journal-title":"J Clin Pharmacol"},{"key":"933_CR9","first-page":"175","volume":"8","author":"J Navarro","year":"2016","unstructured":"Navarro J, Curran A. Profile of once-daily darunavir\/cobicistat fixed-dose combination for the treatment of HIV\/AIDS. HIV AIDS (Auckl). 2016;8:175\u201382.","journal-title":"HIV AIDS (Auckl)"},{"key":"933_CR10","unstructured":"Chromsystems Instruments & Chemicals GmbH. MassTox TDM Series A. 2014 [cited 3 Jun 2020]. https:\/\/www.chromsystems.com\/products\/therapeutic-drug-monitoring\/masstox-tdm-series-a-anti-hiv-drugs-92924.html. Accessed 31 July 2020."},{"key":"933_CR11","doi-asserted-by":"publisher","first-page":"104898","DOI":"10.1016\/j.phrs.2020.104898","volume":"158","author":"D Cattaneo","year":"2020","unstructured":"Cattaneo D, Cattaneo D, Gervasoni C, Corbellino M, Galli M, Riva A, et al. Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res. 2020;158:104898.","journal-title":"Pharmacol Res"},{"issue":"4","key":"933_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/infdis\/jiv123","volume":"212","author":"AH Borges","year":"2015","unstructured":"Borges AH, O\u2019Connor JL, Phillips AN, Ronsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis. 2015;212(4):585\u201395.","journal-title":"J Infect Dis"},{"issue":"1","key":"933_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/FTD.0000000000000576","volume":"41","author":"A Daskapan","year":"2019","unstructured":"Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, et al. Darunavir population pharmacokinetic model based on HIV outpatient data. Ther Drug Monit. 2019;41(1):59\u201365.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"933_CR14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jac\/dkz479","volume":"75","author":"L Dickinson","year":"2020","unstructured":"Dickinson L, Gurjar R, Stohr W, Bonora S, Owen A, D\u2019Avolio A, et al. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate\/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001\/ANRS143 randomized trial. J Antimicrob Chemother. 2020;75(3):628\u201339.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"933_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1389200043335559","volume":"5","author":"KW Renton","year":"2004","unstructured":"Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab. 2004;5(3):235\u201343.","journal-title":"Curr Drug Metab"},{"key":"933_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.pharmtox.46.120604.141059","volume":"46","author":"AE Aitken","year":"2006","unstructured":"Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123\u201349.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"933_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"933_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1124\/dmd.113.052225","volume":"41","author":"R Evers","year":"2013","unstructured":"Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos. 2013;41(9):1598\u2013609.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"933_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease\u2013drug\u2013drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"933_CR20","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome (CRS) in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954.","journal-title":"Int J Antimicrob Agents"},{"key":"933_CR21","doi-asserted-by":"publisher","DOI":"10.7326\/m20-1550","author":"C Schoergenhofer","year":"2020","unstructured":"Schoergenhofer C, Jilma B, Stimpfl T, Karolyi M, Zoufaly A. Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/m20-1550(Epub 12 May 2020).","journal-title":"Ann Intern Med"},{"key":"933_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa195","author":"M Gregoire","year":"2020","unstructured":"Gregoire M, Le Turnier P, Gaborit BJ, Veyrac G, Lecomte R, Boutoille D, et al. Lopinavir pharmacokinetics in COVID-19 patients. J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa195(Epub 22 May 2020).","journal-title":"J Antimicrob Chemother"},{"key":"933_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26111","author":"B Borku Uysal","year":"2020","unstructured":"Borku Uysal B, Ikitimur H, Yavuzer S, Ikitimur B, Uysal H, Islamoglu MS, et al. Tocilizumab challenge: a series of cytokine storm therapy experiences in hospitalized Covid-19 pneumonia patients. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26111(Epub 2 Jun 2020).","journal-title":"J Med Virol"},{"key":"933_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","volume":"76","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43\u20139.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"933_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s13063-020-04447-3","volume":"21","author":"J Rilinger","year":"2020","unstructured":"Rilinger J, Kern WV, Duerschmied D, Supady A, Bode C, Staudacher DL, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):470.","journal-title":"Trials"},{"issue":"2","key":"933_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.2013.79","volume":"94","author":"KK Machavaram","year":"2013","unstructured":"Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, et al. A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther. 2013;94(2):260\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"933_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14314","author":"PF Smith","year":"2020","unstructured":"Smith PF, Dodds M, Bentley D, Yeo K, Rayner C. Dosing will be a key success factor in repurposing antivirals for COVID-19. Br J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bcp.14314(Epub 17 Apr 2020).","journal-title":"Br J Clin Pharmacol"},{"key":"933_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1922","author":"RW Peck","year":"2020","unstructured":"Peck RW, Weiner D, Cook J, Powell JR. A real-world evidence framework for optimising dosing in all patients with COVID-19. Clin Pharmacol Ther. 2020. https:\/\/doi.org\/10.1002\/cpt.1922(Epub 23 May 2020).","journal-title":"Clin Pharmacol Ther"},{"key":"933_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14416","author":"EH Baker","year":"2020","unstructured":"Baker EH, Gnjidic D, Kirkpatrick CMJ, Pirmohamed SM, Wright DFB, Zecharia AY. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments. Br J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bcp.14416(Epub 8 Jun 2020).","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00933-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T23:56:00Z","timestamp":1630022160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00933-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"27 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Udine within the CRUI-CARE Agreement. This research received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"F.P. participated in speaker bureau for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfizer and Sanofi Aventis, and in advisory board for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfizer, Shionogi and Thermo-Fisher. A.L. participated in speaker bureau for Viiv, Gilead, Merck Sharp & Dohme and Janssen. C.T. participated in speaker bureau and received unconditional grants from Angelini, Biomerieux, Biotest, Gilead, Correvio, Hikma, Merck Sharp & Dohme, Pfizer, Shionogi, Thermo-Fisher, and Nordic Pharma. All other authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Regional Ethics Committee of Friuli Venezia Giulia Region, Italy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"In light of the retrospective nature of the study, informed written consent was waived, according to the institutional policies for studies with a retrospective design.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"In light of the retrospective nature of the study, informed written consent was waived, according to the institutional policies for studies with a retrospective design.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PGC and FP conceptualized the study, performed the analysis and drafted the manuscript; AL, PDS and FG acquired and interpreted clinical data; MF and JB performed the laboratory analysis; FP and CT supervised the project and reviewed the entire contents of the manuscript. All authors have read and agree to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}